Search
Abstract
According to the World Anti-Doping Agency (WADA) Prohibited List, glucocorticosteroids are prohibited in competition and only when administered by oral, intravenous, intramuscular or rectal routes. Up to now, in order to differentiate whether glucocorticosteroids were administered by one of the prohibited routes or not, a specific reporting limit for urinary concentrations of parent compounds and their metabolites was established at 30 ng/mL. Additionally, the new specific regulation starting from 1 September 2014 for budesonide have been introduced that the β-hydroxybudesonide shall be targeted. Budesonide is a glucocorticosteroid used mainly by inhalation for asthma management. Interestingly, anti-doping laboratory statistics show that budesonide adverse analytical findings (AAF) constitute almost 50% of all reported glucocorticosteroid AAFs, even though budesonide possesses a very low systemic activity which may cause performance enhance effects. This work presents the results of five studies of controlled budesonide administration carried out on professional athletes. The samples were analyzed by using a quantitative HPLC/MS/MS method for 16α-hydroxyprednisolone, the most abundant budesonide metabolite in urine. Our data clearly show that inhalation of budesonide at least 12 h before a competition at therapeutic doses leads to appearance of the main budesonide metabolite in concentrations exceeding prior reporting limit for this compound.
Authors (9)
-
Paweł Kaliszewski
- Institute of Sport, Warszawa Department of Anti-Doping Research
-
Danuta Kończak
- Institute of Sport, Warszawa Department of Anti-Doping Research
-
Piotr Chołbiński
- Institute of Sport, Warszawa Department of Anti-Doping Research
-
Mariola Wicka
- Institute of Sport, Warszawa Department of Anti-Doping Research
-
Dorota Michalak
- Institute of Sport, Warszawa Department of Anti-Doping Research
-
Dorota Kwiatkowska dr inż.
- Institute of Sport, Warszawa Department of Anti-Doping Research
-
Sylwia Lewandowska-Pachecka
- Medical University of Warsaw Faculty of Pharmacy
-
Andrzej Pokrywka
- University of Zielona Góra Faculty of Medicine and Health Sciences
Cite as
Full text
- Publication version
- Accepted or Published Version
- License
-
open in new tab
Keywords
Details
- Category:
- Articles
- Type:
- artykuł w czasopiśmie wyróżnionym w JCR
- Published in:
-
Acta Poloniae Pharmaceutica - Drug Research
no. 73,
pages 229 - 237,
ISSN: 0001-6837 - Language:
- English
- Publication year:
- 2016
- Bibliographic description:
- Kaliszewski P., Kończak D., Chołbiński P., Wicka M., Michalak D., Kwiatkowska D., Lewandowska-Pachecka S., Namieśnik J., Pokrywka A.: Budesonide treatment of professional athletes and anti-doping testing- case studies// Acta Poloniae Pharmaceutica - Drug Research. -Vol. 73, nr. 1 (2016), s.229-237
- Verified by:
- Gdańsk University of Technology
seen 463 times
Recommended for you
Abuse or contamination? Ratio determination of clenbuterol enantiomers to distinguish between doping use and meat contamination
- M. Thijs,
- M. K. Parr,
- M. Blokland
- + 6 authors
Electrochemical oxidation of PFOA and PFOS in landfill leachates at low and highly boron-doped diamond electrodes
- M. Pierpaoli,
- M. Szopińska,
- B. Wilk
- + 4 authors